<DOC>
	<DOCNO>NCT02241031</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ex vivo generate megakaryocytic progenitor cell ( MPs ) prophylaxis treatment thrombocytopenia cause chemotherapy patient acute leukemia ( AL ) .</brief_summary>
	<brief_title>Megakaryocytic Progenitor Cells Prophylaxis Treatment Thrombocytopenia</brief_title>
	<detailed_description>Thrombocytopenia common potentially fatal complication chemotherapy hematopoietic stem cell transplantation . Owing short storage time increase demand platelet unrelated donor , constant shortage supply platelets become important medical society challenge . Therefore , investigation alternative source platelet would beneficial . Hematopoietic stem cell ( HSCs ) use generate functional megakaryocytic progenitor ( MPs ) , megakaryocytes , platelet large scale . Functional MPs platelet successfully produce vitro CD34+ hematopoietic cell bone marrow , cord blood , peripheral blood . Several study report transplantation vitro auto-producing MPs promote platelet recovery high-dose therapy HSC transplantation . Umbilical cord blood abundant source HSCs . In vitro large scale production MPs cord blood could represent effective platelet substitute . Theoretically , additional transplantation ex vivo generate progenitor post-progenitor cell might lead production sufficient number mature functional cell within day transplantation .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>age：1465 year achieve complete remission acute leukemia first course consolidation chemotherapy ECOG grade 0 1 expect survival time ≥ three month Subjects ( legally acceptable representative ) must sign informed consent document . cardiac dysfunction ( particularly congestive heart failure ) , hepatic abnormality ( bilirubin ≥ 3 mg/dL , aminotransferase &gt; 2 time upper limit normal ) , renal dysfunction ( creatinine clearance rate &lt; 30 mL/min ) Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Megakaryocytic Progenitor Products</keyword>
	<keyword>Hematological Diseases</keyword>
	<keyword>Thrombocytopenia</keyword>
</DOC>